EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKI) have been reported to significantly improve progression-free survival (PFS) in metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations compared with systemic therapy alone.